Free Primary Care CME

Upon completion of this activity, learners will be able to:

• Implement routine OSA screening for patients with obesity and other OSA risk factors.
• Identify tools that can aid in screening patients for OSA.
• Initiate diagnostic workups for patients with suspected OSA.
• Evaluate results from OSA diagnostic studies.
• Implement multidisciplinary approaches to formulate tailored management strategies for OSA that account for patient preferences and new therapeutic options.

In this MedX activity, Michael Blaha, MD, explores the evolving landscape of low-density lipoprotein cholesterol (LDL-C) management in patients with atherosclerotic cardiovascular disease (ASCVD), with a focus on the current role of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and how emerging novel PCSK9 inhibitor formulations may be integrated into clinical practice as they become available.

Bronchiectasis is a complex and increasingly prevalent condition often overlooked in clinical practice, with frequent overlap with other respiratory diseases such as COPD and asthma. Persistent airway inflammation, chronic infection, and mucociliary dysfunction drive disease progression, leading to significant morbidity and healthcare burden. As the clinical burden of bronchiectasis becomes increasingly recognized, there is an urgent need to better understand the underlying mechanisms of neutrophilic inflammation, alongside efforts to improve early diagnosis and explore current and emerging treatment options that target this vicious cycle.

In this activity, a panel of leading pulmonologists tackle the evolving challenges and emerging opportunities in bronchiectasis management. From diagnostic workup to airway clearance and exacerbation control, the discussion will blend expert insight with real-world clinical scenarios and patient perspectives.
Endocrinologists, endocrinology NPs and PAs, and the broader care team are positioned to close it. This training program, modeled on the CDC Training of Trainers approach, equips endocrinology-led teams to build CKM risk into everyday T2D decision-making: selecting and sequencing GLP-1-based therapies according to a patient’s cardiovascular, renal, and metabolic profile, not glycemic control alone. The content also addresses related benefits emerging in this drug class, including MASH and OSA, within the broader CKM framework.Designed to update clinicians on data presented at the American Society of Retina Specialists 43rd Annual Meeting held in Long Beach, CA, from July 30 to August 2, 2025
Expert thought leaders provide insights to help clinicians apply these findings to their management of patients with nAMD, DME, and RVO when using newer therapies that support longer treatment intervals.

This accredited activity reviews advancements in lung transplant surgery, with a focus on robotic lung transplant and ex vivo lung perfusion.

In this brief 15-minute activity, you will:

– Follow the case of a patient who presents with foot drop and no other medical conditions
– Choose optimal management approaches by answering nongraded questions within the activity (answers are collected for informational purposes only and used to assess the effectiveness of this educational activity)
– See how your answers compare with those of your peers
– View video clips providing expert insights

Meet a 52-year-old woman with type 2 diabetes and hypertension whose recent laboratory results reveal a decline in kidney function. How would you manage this patient? In this 15-minute activity, read about next steps in the management of advanced kidney disease.